dc.contributorFaculty of Medicine ABC
dc.contributorEstacio Faculty of Medicine
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:29:32Z
dc.date.available2014-05-27T11:29:32Z
dc.date.created2014-05-27T11:29:32Z
dc.date.issued2013-05-28
dc.identifierInternational Archives of Medicine, v. 6, n. 1, 2013.
dc.identifier1755-7682
dc.identifierhttp://hdl.handle.net/11449/75446
dc.identifier10.1186/1755-7682-6-24
dc.identifier2-s2.0-84878007738
dc.identifier2-s2.0-84878007738.pdf
dc.description.abstractBackground: Osteoporosis is a disease of bone metabolism in which bisphosphonates (BPS) are the most common medications used in its treatment, whose main objective is to reduce the risk of fractures. The aim of this study was to conduct a systematic review on BPs adherence for treatment of osteoporosis. Methods. Systematic review of articles on BPs adherence for treatment of osteoporosis, indexed on MEDLINE (via PubMed) databases, from inception of databases until January 2013. Search terms were Adherence, Medication (MeSH term), Bisphosphonates (MeSH term), and Osteoporosis (MeSH term). Results: Of the 78 identified studies, 27 met the eligibility criteria. Identified studies covered a wide range of aspects regarding adherence and associated factors, adherence and fracture, adherence and BPs dosage. The studies are mostly observational, conducted with women over 45 years old, showing low rates of adherence to treatment. Several factors may influence adherence: socio-economic and cultural, participation of physicians when guidance is given to the patient, the use of bone turnover markers, and use of generic drugs. The monthly dosage is associated with greater adherence compared to weekly dosage. Conclusions: Considering the methodological differences between the studies, the results converge to show that adherence to treatment of osteoporosis with BPs is still inadequate. Further experimental studies are needed to evaluate the adherence and suggest new treatment options. © 2013 Vieira et al.; licensee BioMed Central Ltd.
dc.languageeng
dc.relationInternational Archives of Medicine
dc.relation0,237
dc.rightsAcesso aberto
dc.sourceScopus
dc.subjectBisphosphonates
dc.subjectBone and bones
dc.subjectMedication adherence
dc.subjectOsteoporosis
dc.subjectalendronic acid
dc.subjectbisphosphonic acid derivative
dc.subjectclodronic acid
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitor
dc.subjectibandronic acid
dc.subjectrisedronic acid
dc.subjectbone densitometry
dc.subjectbone turnover
dc.subjectdrug use
dc.subjecthip fracture
dc.subjecthuman
dc.subjectmedication compliance
dc.subjectosteoporosis
dc.subjectpatient compliance
dc.subjectpatient counseling
dc.subjectrandomized controlled trial (topic)
dc.subjectrural area
dc.subjectsmoking
dc.subjectspine fracture
dc.subjectsystematic review
dc.subjecttreatment duration
dc.subjecttreatment refusal
dc.titleBisphosphonates adherence for treatment of osteoporosis
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución